India’s flagship pharmaceutical incentive scheme has drawn nearly three times the investment it sought. Yet the Centre has just granted its MSME participants an extra year, a signal that scale, capital and compliance remain the dividing line in Indian pharma.
On paper, the Production Linked Incentive Scheme for Pharmaceuticals is one of the clearest successes of India’s manufacturing policy. Against a targeted investment of 17,275 crore rupees, participating companies had put in 46,744 crore rupees by June 2026, according to the Department of Pharmaceuticals. Yet on 30 October the same department issued a corrigendum giving the scheme’s micro, small and medium enterprises one more year to complete their committed investments. The two facts sit awkwardly together, and the gap between them is the subject of Express Pharma’s November cover story, which asks whether MSMEs can catch up.
What ‘PLI 2.0’ means
The label needs explaining, because it is used loosely. The first pharmaceutical PLI, launched in 2020, targeted bulk drugs: key starting materials, intermediates and active pharmaceutical ingredients for which India depends heavily on imports. The second scheme, notified in March 2021 with an outlay of 15,000 crore rupees and commonly called PLI 2.0, aims higher up the value chain. It rewards incremental sales of complex generics, biopharmaceuticals, patented and off-patent medicines, orphan drugs and similar high-value products, and runs to 2028-29.
Participants were sorted by size. Group A comprised companies with global manufacturing revenue above 5,000 crore rupees, Group B those between 500 and 5,000 crore, and Group C those below 500 crore, with a sub-category reserved for MSMEs. Of the 55 companies selected, 11 were in Group A, nine in Group B and 35 in Group C, including 20 MSMEs.
A scheme tilted by design
The allocation reveals the policy’s centre of gravity. Of the 15,000 crore rupees, 11,000 crore was earmarked for Group A, 2,250 crore for Group B and 1,750 crore for Group C. The incentive ceiling per company was set at 1,000 crore rupees for the largest firms and 50 crore for the smallest. The logic was explicit: build national champions able to compete in global value chains.
That logic has largely worked for the large exporters, who had products, regulatory filings and overseas customers ready. Much of the investment overshoot is understood to have come from them. For a small manufacturer the arithmetic is different. Incentives are paid on incremental sales of eligible products, after investment thresholds are met. A firm must first raise capital, build or upgrade a plant, develop a qualifying product and win approvals, often in regulated markets, before any incentive arrives.
Why smaller firms fall behind
Several pressures converged on pharmaceutical MSMEs during the scheme’s life. The cost of capital is higher for small borrowers. The revised Schedule M norms on good manufacturing practice, tightened after a series of quality failures in exported medicines, require smaller units to invest in facilities, documentation and quality systems simply to keep their licences, leaving less for expansion. Complex generics and biologics need development skills and analytical infrastructure that few small firms possess. And export markets have become harder, with pricing pressure in the United States and tariff uncertainty.
The October corrigendum acknowledges this. It moves each investment milestone for Group C MSME participants forward by one financial year, so that the full committed investment is now due by 2026-27 instead of 2025-26. The relief is limited: the sales conditions and the period over which incentives are calculated remain unchanged, so a firm that invests later has fewer years in which to earn.
What ‘catching up’ would require
Industry voices have long argued that a scheme built on sales growth favours those already growing. Suggestions for a next phase include a separate window for MSMEs with lower thresholds, credit support linked to plant upgradation, and incentives for shared infrastructure such as testing laboratories and effluent treatment plants in pharmaceutical clusters. Some of this exists outside PLI, through the department’s Strengthening of Pharmaceutical Industry schemes, which subsidise technology upgradation and common facilities.
There is also a precedent in the neighbouring sector. This month the government extended the PLI scheme for medical devices to 2035-36 with an outlay of 2,700 crore rupees, removed the minimum sales threshold, lowered the minimum investment and reorganised the scheme around components and manufacturing depth. Observers see that as a model for a more MSME-friendly design, though the pharmaceutical scheme has not been revised in the same way.
A point of caution for readers: at the time of writing, we could find no official notification of a new, third pharmaceutical PLI. The debate is about how the existing scheme performs for its smallest participants in its closing years, and what any successor should look like.
The quality dimension
For a publication concerned with laboratory science, one aspect deserves emphasis. The route from a low-margin generic to a complex product runs through analytical capability: impurity profiling, stability studies, bioequivalence support and data integrity that will survive a foreign regulator’s inspection. These are precisely the investments MSMEs find hardest to finance, and they are not rewarded directly by a sales-linked incentive. A small firm that upgrades its quality control laboratory improves its prospects in every market, whether or not it ever earns a PLI rupee.
The larger stake
India has roughly ten thousand pharmaceutical manufacturing units, the great majority of them small. They supply much of the domestic market’s affordable medicine and a significant share of exports to developing countries. If incentives lift only the top tier, the industry risks a two-speed structure: globally competitive leaders, and a long tail squeezed between compliance costs and thin margins.
The scheme’s headline numbers show that Indian pharma will invest when the reward is clear. The extension granted to its smallest participants shows that for MSMEs, time and capital are scarcer than ambition. Whether the next round of policy narrows that gap will matter as much as the total invested.
